Go to the list of all blogs
Allana's Avatar
published in Blogs
Jul 29, 2026
Camtek Ltd. (CAMT) Stock Declines -19% Over 30 Days: Analyzing the Pullback

Camtek Ltd. (CAMT) Stock Declines -19% Over 30 Days: Analyzing the Pullback

Key Takeaways

  • Camtek Ltd. (CAMT) shares declined approximately 19% in the last 30 days, falling from $157.32 on June 29 to $126.97 on July 29, 2026.
  • The sell-off extends a broader downtrend that began after the stock hit its 52-week high of $215.99 on May 11, representing a total drawdown of roughly 41% from peak to current levels.
  • A combination of cooling AI hardware sentiment, competitive concerns raised by analysts, dilution fears from a shelf registration filing, and heavy selling in Israeli semiconductor names drove the decline.
  • Quarterly performance shows an approximate 32% drop, with the stock falling from $187.83 at the end of April to current levels, despite strong order momentum and raised revenue guidance.
  • Camtek's underlying business remains robust, with management projecting over 25% revenue growth in the second half of 2026 and more than $260 million in expected revenue from HBM manufacturers through 2027.
  • Investors are closely watching the upcoming Q2 2026 earnings report, expected in early August, as a critical catalyst for validating the company's growth trajectory.

Camtek Ltd. (CAMT) Business Overview

Camtek Ltd. is an Israel-based provider of automated optical inspection and metrology solutions serving the semiconductor and printed circuit board industries. The company develops, manufactures, and markets inline and stand-alone systems that perform high-resolution 2D and 3D measurements, defect detection, and process control. Its equipment is used by integrated device manufacturers, foundries, outsourced semiconductor assembly and test providers, and PCB fabricators worldwide to optimize manufacturing yields and reduce production costs.

Camtek has carved out a leading position in the advanced packaging inspection market, which has become increasingly critical as chipmakers adopt chiplet-based architectures and high-bandwidth memory for AI and high-performance computing applications. Approximately 70% of Camtek's revenue is tied to the advanced packaging segment, positioning the company at the center of the AI-driven semiconductor investment cycle. With a market capitalization of approximately $6.5 billion, CAMT is followed closely by investors seeking exposure to the AI infrastructure build-out through semiconductor capital equipment. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Recent Price Action in CAMT Shares

Over the last 30 calendar days, CAMT shares have declined approximately 19%, falling from a closing price of $157.32 on June 29, 2026, to an intraday level of $126.97 on July 29. The selling pressure intensified in late July, with shares dropping more than 7% on consecutive trading sessions on July 27 and July 28 amid a broader sell-off in Israeli-listed semiconductor stocks, including TSEM and NVMI.

Zooming out to the quarterly view, the decline is even steeper. From the end of April 2026, when shares closed at approximately $187.83, CAMT has shed roughly 32% of its value. The stock reached its all-time closing high of $215.99 on May 11, only to plunge 16.8% on May 12 following its Q1 2026 earnings release, which beat analyst expectations but failed to satisfy elevated market expectations after a massive year-to-date rally. The stock briefly recovered to the $195–$205 range in mid-June before resuming its downward trajectory through July.

Factors Behind the Recent 30-Day Decline

Several converging factors drove the steep 30-day decline in CAMT shares. Foremost among them was a sharp cooling of AI-related semiconductor sentiment. Samsung's latest earnings report and reports that major technology companies were offloading excess AI compute equipment raised fears that the AI hardware investment cycle may be approaching a peak, triggering a broad valuation reset across semiconductor equipment names.

Competitive dynamics also weighed on the stock. Cantor Fitzgerald maintained a Neutral rating and pointed to increasing competitive risks from ONTO Innovation and KLAC in the advanced packaging inspection space. Morgan Stanley issued an Equal-weight rating with a lowered price target of $167 on July 6, further dampening bullish sentiment.

Corporate governance concerns added another layer of pressure. Camtek filed a shelf registration to issue up to one million new shares, raising fears of potential dilution at a time when the stock was already under significant selling pressure. The company's upcoming annual general meeting also drew scrutiny for proposals viewed by some investors as favoring insiders, including the extension of special registration rights through 2031.

Finally, a concentrated sell-off in Israeli semiconductor stocks in late July—driven by regional market dynamics on the Tel Aviv Stock Exchange—accelerated the decline, with Camtek falling alongside peers Tower Semiconductor and Nova Ltd. in high-volume trading sessions. From what I see, this combination of sentiment shift and sector-specific pressure was particularly impactful.

Broader Quarterly Trends and Valuation Reset

The broader quarterly decline of approximately 32% tells a story of valuation compression following an extraordinary rally. Prior to the sell-off, CAMT had surged roughly 80% year-to-date, reaching a peak valuation that priced in exceptionally high growth expectations. When the company reported Q1 2026 results on May 12—delivering revenue of $121.7 million and EPS of $0.70, both modestly above consensus—the beat was not large enough to sustain the elevated multiple in a market that had begun rotating away from richly valued semiconductor names.

A hotter-than-expected Consumer Price Index reading on the same day as earnings catalyzed a broad-based semiconductor sell-off, and Camtek was among the hardest hit. Throughout the quarter, profit-taking, sector rotation, and growing concerns about the sustainability of AI capital expenditure growth continued to pressure the stock. Despite management's upbeat commentary—including guidance for over 25% second-half revenue growth and more than $260 million in expected HBM-related revenue through 2027—the market increasingly focused on competitive risks, customer concentration in Asia, and the possibility that order momentum had already been priced in.

Looking Ahead: Key Catalysts for CAMT

The primary near-term catalyst for CAMT is its Q2 2026 earnings report, expected around early August. Investors will scrutinize whether the company can convert its record order backlog—including the $105 million in multi-system orders announced in late June—into reported revenue growth that validates management's bullish second-half guidance. Gross margin trends will be particularly important, as the company has signaled expectations for improvement driven by higher volumes and an increasing revenue contribution from its higher-margin Eagle G5 and Hawk platforms.

Beyond earnings, several macro and industry factors demand attention. The trajectory of AI capital expenditure among hyperscale cloud providers and major semiconductor manufacturers will directly influence demand for Camtek's inspection and metrology tools. Competitive developments from Onto Innovation and KLA in the advanced packaging inspection market could impact Camtek's market share narrative. Additionally, geopolitical risks related to Camtek's significant exposure to Asian markets—including China, Korea, and Taiwan—and the ongoing security situation in Israel, where most of the company's manufacturing and R&D is concentrated, remain important considerations for investors evaluating the stock's risk profile. I’m watching this closely as the earnings date approaches.

Using Tickeron’s Trending AI Robots for Market Insights

One resource I turn to when looking for additional perspectives on market movements is Tickeron’s Trending AI Robots. This section highlights bots with strong real-time performance across various strategies, which can help supplement fundamental research on names like CAMT without replacing core analysis.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: CAMT

Contributor

Allana's AvatarAllana|Expert

Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.


CAMT in upward trend: price may jump up because it broke its lower Bollinger Band on July 29, 2026

CAMT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 30 cases where CAMT's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where CAMT's RSI Indicator exited the oversold zone, of 28 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for CAMT just turned positive on August 04, 2026. Looking at past instances where CAMT's MACD turned positive, the stock continued to rise in of 53 cases over the following month. The odds of a continued upward trend are .

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where CAMT advanced for three days, in of 340 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

The Momentum Indicator moved below the 0 level on July 28, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CAMT as a result. In of 98 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CAMT declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for CAMT entered a downward trend on August 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 64, placing this stock slightly better than average.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. CAMT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (10.235) is normal, around the industry mean (8.253). P/E Ratio (154.381) is within average values for comparable stocks, (173.765). CAMT's Projected Growth (PEG Ratio) (3.082) is very high in comparison to the industry average of (1.534). CAMT's Dividend Yield (0.020) is considerably higher than the industry average of (0.006). P/S Ratio (15.152) is also within normal values, averaging (35.325).

Notable companies

The most notable companies in this group are Applied Materials (NASDAQ:AMAT), Lam Research Corp (NASDAQ:LRCX), KLA Corporation (NASDAQ:KLAC), Teradyne (NASDAQ:TER), Ambarella (NASDAQ:AMBA).

Industry description

The electronic production equipment industry makes equipment used to produce semiconductors. Such equipment includes wafer fabrication, plasma etching and photo-resist processing equipment. The industry also makes chemical vapor deposition processing systems and photomasks, which are high-purity quartz plates that contain patterns to define integrated circuits layouts. Applied Materials, Inc., Lam Research Corporation, and KLA-Tencor Corporation are examples of electronic production equipment manufacturing companies.

Market Cap

The average market capitalization across the Electronic Production Equipment Industry is 64.45B. The market cap for tickers in the group ranges from 555.66K to 663.18B. ASML holds the highest valuation in this group at 663.18B. The lowest valued company is AVSR at 555.66K.

High and low price notable news

The average weekly price growth across all stocks in the Electronic Production Equipment Industry was 8%. For the same Industry, the average monthly price growth was -1%, and the average quarterly price growth was 46%. AXTI experienced the highest price growth at 60%, while SMTK experienced the biggest fall at -26%.

Volume

The average weekly volume growth across all stocks in the Electronic Production Equipment Industry was -47%. For the same stocks of the Industry, the average monthly volume growth was -41% and the average quarterly volume growth was -68%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 64
P/E Growth Rating: 34
Price Growth Rating: 43
SMR Rating: 74
Profit Risk Rating: 64
Seasonality Score: -23 (-100 ... +100)
View a ticker or compare two or three
CAMT
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

a developer of automatic optical inspection systems and related products

Industry ElectronicProductionEquipment

Profile
Details
Industry
Electronic Production Equipment
Address
Ramat Gavriel Industrial Zone
Phone
+972 46048100
Employees
709
Web
https://www.camtek.com
Interact to see
Advertisement
Novartis (NVS) reports Q4/FY 2025 earnings on February 4, 2026, with consensus calling for ~$1.99 EPS on ~$13.7 billion in revenue. Sanofi (SNY) delivered strong FY 2025 results on January 29, reporting €43.6 billion in sales (+9.9% CER) and 15% business EPS growth.
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
MUFG is expected to report Q3 FY2026 EPS of about $0.30, broadly in line with its recent pattern of earnings beats.
Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Arm, the leading provider of energy-efficient processor designs powering over 99% of smartphones and expanding into AI data centers, faces high scrutiny in Q3 FY2026 (ending Dec 31, 2025). After a strong Q2 with record royalty and licensing revenue, investors are focused on whether AI demand will continue to drive robust growth.
CME Group (CME): Q4 2025 earnings due February 4, 2026; consensus expects adjusted EPS $2.75 and revenue ~$1.6B. S&P Global (SPGI): Q4 2025 earnings due February 10, 2026; Q3 posted EPS $4.73 and 9% revenue growth, driven by Ratings, Indices, and Market Intelligence.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.